TPI 287 in Patients With Refractory or Recurrent Neuroblastoma or Medulloblastoma
A Phase 1 Trial of TPI 287 as a Single Agent and in Combination With Temozolomide in Patients With Refractory or Recurrent Neuroblastoma or Medulloblastoma
Sponsor: Cortice Biosciences, Inc.
A PHASE1 clinical study on Medulloblastoma and Neuroblastoma, this trial is completed. The trial is conducted by Cortice Biosciences, Inc. and has accumulated 10 data snapshots since 2009. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
10 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE1
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
May 2024 — Jul 2024 [monthly]
Completed PHASE1
-
Oct 2023 — May 2024 [monthly]
Completed PHASE1
▶ Show 5 earlier versions
-
May 2022 — Oct 2023 [monthly]
Completed PHASE1
-
Jan 2021 — May 2022 [monthly]
Completed PHASE1
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE1
-
Feb 2017 — Jun 2018 [monthly]
Completed PHASE1
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE1
First recorded
Mar 2009
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Cortice Biosciences, Inc.
- Giselle Sholler
For direct contact, visit the study record on ClinicalTrials.gov .